ClinicalTrials.gg
RecruitingNCT06570798Updated Oct 5, 2026

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

A Phase 2 interventional study of Inebilizumab and Blinatumomab in Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis, sponsored by Amgen. Recruiting at 58 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lupus Erythematosus, Systemic by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Amgen.

Planned enrollment
2nd of 20
220 · median 56
Started
2025
the only one that year
Phase 2
5 of 20
1 open now
Registered
20th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Amgen, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 2, and was the 20th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 20 studies in Lupus Erythematosus, Systemic by Amgen is open now, in 10 countries.

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Amgen, or all of them as a file.
02

Study summary

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Active Refractory Rheumatoid Arthritis

Keywords

  • Systemic lupus erythematosus
  • Inebilizumab
  • Blinatumomab
  • Active refractory rheumatoid arthritis
  • Rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

*Subprotocol A and B are no longer recruiting participants*

Inclusion criteria

Inclusion Criteria:

  • Subprotocol A and B: Diagnosis of SLE according to 2019 European League Against Rheumatism and the American College of Rheumatology (ACR) classification criteria.
  • Subprotocol A and B: Participant must be positive for at least one of the following autoantibodies at screening (performed by central laboratory) or through documented history:

    1. Antinuclear antibodies (ANA) ≥ 1:80
    2. Anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies elevated to above normal range (ie, positive results)
    3. AntiSmith antibodies elevated to above normal (ie, positive results).
  • Subprotocol A and B (Subgroup 1): Active, -proven, proliferative LN demonstrating class III or class IV with or without co-existing features of Class V LN (or pure Class V LN for Subprotocol B only) according to 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria. The local biopsy report will be used.
  • Subprotocol A and B: SLE Disease Activity Index 2K ≥ 6.
  • Subprotocol A and B (Subgroup 1): Inadequate response, loss of response or intolerance to at least 1 therapy (Subprotocol A) or 2 therapies (Subprotocol B Subgroup 1) at the maximally tolerated doses as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (KDIGO, 2024). Inadequate response is defined as: UPCR ≥ 1.0 mg/mg.
  • Subprotocol B (Subgroup 2): SLE participants with inadequate response to multiple therapies (excluding hydroxychloroquine or ) and have failed either a biologic agent or cyclophosphamide.
  • Subprotocol B (Part B Subgroup 2): British Isles Lupus Assessment Group (BILAG)-2004 level A disease in 1 organ system or BILAG-2004 level B disease in ≥ 2 organ systems
  • Subprotocol B (Part B Subgroup 2): Physician Global Assessment (PGA) ≥ 1
  • Subprotocol A and B: If receiving any of the following medications, participants must be on these doses prior to Day 1:

    1. Prednisone dose ≤ 20 mg/day (or its equivalent in other corticosteroid forms) and at a stable dose for 5 days
    2. Hydroxychloroquine dose ≤ 400 mg/day and at a stable dose for 4 weeks. Other equivalent antimalarials (chloroquine, quinacrine) are also accepted at a stable dose for 4 weeks.
    3. MMF dose ≤ 3 g/day or MPA dose ≤ 2160 mg/day and at a stable dose for 2 weeks.
    4. AZA dose ≤ 2 mg/kg/day and at a stable dose for 2 weeks.
    5. Methotrexate > 25 mg/week and at a stable dose for 2 weeks
    6. Leflunomide > 20 mg/day and at a stable dose for 2 weeks
    7. Dapsone > 300 mg/day and at a stable dose for 2 weeks.
  • Subprotocol C (Part A and Part B): Diagnosis of RA according to the 2010 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria.
  • Subprotocol C (Part A and Part B): Moderate to severe disease activity as defined by DAS28-CRP > 3.2 with ≥ 3 swollen joints and ≥ 3 tender joints (based on 28 joint counts) at screening.
  • Subprotocol C (Part A and Part B): Refractory disease defined as:
  • Active disease despite having received treatment with:

    1. at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD), AND
    2. at least 2 biologic disease-modifying antirheumatic drugs (bDMARDs) of different mechanisms of action OR 1 bDMARD and at least 1 targeted synthetic disease-modifying antirheumatic drugs (tsDMARD).
  • Inadequate response or intolerance to csDMARDs, bDMARDs, and tsDMARDs should be defined as:

    1. Participant having active disease despite a minimum of 12 weeks of treatment with a csDMARD, bDMARD, or tsDMARD.
    2. Intolerance to treatment as defined by participant having experienced an adverse effect from treatment with a csDMARD, bDMARD, or tsDMARD.
  • Subprotocol C (Part B): High sensitivity C-Reactive Protein (hsCRP) level ≥ per the central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

  • Subprotocol A, B and C: Receipt of a live and/or within 4 weeks prior to first dose of trial drug, during the treatment period, or until B-cell repletion after the end of the treatment period. Administration of inactivated (killed) vaccines is acceptable.
  • Subprotocol A and B: Estimated (eGFR) of \< 30 mL per minute per 1.73 m\^2 of body surface area (calculated using the Modification of Diet in Renal Disease [MDRD] formula, with screening laboratory results for serum creatinine value).
  • Subprotocol A and B: Significant likely irreversible organ damage related to SLE (eg, end-stage renal disease [ESRD]).
  • Subprotocol A and B: Any acute, severe lupus related flare during screening that needs immediate treatment.
  • Subprotocol A and B: A previous kidney transplant or planned transplant within trial treatment period.
  • Subprotocol A and B: History of or current renal diseases (Parts A and B, Subgroup 1) that in the opinion of the investigator could interfere with the LN assessment and confound the disease activity assessment (eg, diabetic nephropathy).
  • Subprotocol A: Renal showing pure class V.
  • Subprotocol B: Active CNS Lupus within one year prior to screening.
  • Subprotocol B and C: History or presence of central nervous system (CNS) pathology or event such as seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or organic brain syndrome.
  • Subprotocol C: Prior history of current inflammatory joint disease other than RA including but not limited to SLE, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (eg, vasculitis, pulmonary fibrosis, or Felty's syndrome).
  • Subprotocol C: Functional Class IV as defined by the ACR classification of functional status in RA.
  • Subprotocol A, B and C: Receipt of the following medications or treatments at any time prior to Day 1:

    1. B-cell directed CAR T-cell and T-cell engager therapies
    2. Total lymphoid irradiation
    3. Bone marrow transplant
    4. T-cell vaccination therapy
    5. Natalizumab
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Subprotocol A: Inebilizumab 3 Doses

    Participants will receive 3 doses of inebilizumab administered via an intravenous (IV) infusion.

    Drug: Inebilizumab

  • Experimental
    Subprotocol A: Inebilizumab 4 Doses

    Participants will receive 4 doses of inebilizumab administered via an IV infusion.

    Drug: Inebilizumab

  • Experimental
    Subprotocol B Part A: Blinatumomab Low-dose

    Participants will receive blinatumomab low-dose administered via SC injection.

    Drug: Blinatumomab

  • Experimental
    Subprotocol B Part A: Blinatumomab Medium-dose

    Participants will receive blinatumomab medium-dose administered via SC injection.

    Drug: Blinatumomab

  • Experimental
    Subprotocol B Part A: Blinatumomab High-dose

    Participants will receive blinatumomab high-dose administered via SC injection.

    Drug: Blinatumomab

  • Experimental
    Subprotocol B Part B: Dose Expansion

    Participants will receive blinatumomab at a dose which will be determined during Subprotocol B Part A.

    Drug: Blinatumomab

  • Experimental
    Subprotocol C Part A: Blinatumomab Low-dose

    Participants will receive blinatumomab low-dose administered via SC injection during Subprotocol C Part A.

    Drug: Blinatumomab

  • Experimental
    Subprotocol C Part A: Blinatumomab Medium-dose

    Participants will receive blinatumomab medium-dose administered via SC injection during Subprotocol C Part A.

    Drug: Blinatumomab

  • Experimental
    Subprotocol C Part A: Blinatumomab High-dose

    Participants will receive blinatumomab high-dose administered via SC injection during Subprotocol C Part A.

    Drug: Blinatumomab

  • Experimental
    Subprotocol C Part B: Dose Expansion

    Participants will receive blinatumomab at a dose which will be determined during Subprotocol C Part A.

    Drug: Blinatumomab

Interventions

06

What researchers measure

Primary outcomes

  1. Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)

    Time frame: Day 1 to Week 52

  2. Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Serious TEAE

    Time frame: Day 1 to Week 52

  3. Subprotocol B Part B Subgroup 1: Number of Participants With Complete Renal Response (CRR)

    Time frame: Week 52

  4. Subprotocol B Part B Subgroup 2: Number of Participants With Remission in SLE as Defined by Definition of Remission in SLE (DORIS)

    Time frame: Week 26

  5. Subprotocol C Part B: Percentage of Participants Achieving Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP) Remission

    Time frame: Week 12

Secondary outcomes

  1. Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With CRR

    Time frame: Subprotocol A and B Part A: Week 12, Week 26, Week 38, and Week 52; Subprotocol B Part B: Week 12, Week 26, and Week 38

  2. Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With Partial Renal Response (PRR)

    Time frame: Week 12, Week 26, Week 38, and Week 52

  3. Subprotocol A and B: Number of Participants With Remission in SLE as Defined by DORIS

    Time frame: Subprotocol A, B Part A, and B Part B Subgroup 1: Week 12, Week 26, Week 38, and Week 52; Subprotocol B Part B Subgroup 2: Week 12, Week 38, and Week 52

  4. Subprotocol A and B: Number of Participants With a Lupus Low Disease Activity State (LLDAS)

    Time frame: Week 12, Week 26, Week 38, and Week 52

  5. Subprotocol A and B: Change From Baseline in SLE Activity Index-2000 (SLEDAI-2K) Score

    Time frame: Week 12, Week 26, Week 38, and Week 52

  6. Subprotocol A, B Part A Subgroup 1 and Part B Subgroup 1: Change From Baseline in 24-hour UPCR

    Time frame: Week 12, Week 26, Week 38, and Week 52

  7. Subprotocol A: Maximum Concentration (Cmax) of Inebilizumab

    Time frame: Day 1 to Week 52

  8. Subprotocol A: Time to Cmax (tmax) of Inebilizumab

    Time frame: Day 1 to Week 52

  9. Subprotocol A: Area Under the Concentration-time Curve (AUC) of Inebilizumab

    Time frame: Day 1 to Week 52

  10. Subprotocol B and C: Cmax of Blinatumomab

    Time frame: up to Week 12

  11. Subprotocol B and C: tmax of Blinatumomab

    Time frame: up to Week 12

  12. Subprotocol B and C: AUC of Blinatumomab

    Time frame: up to Week 12

  13. Subprotocol A: Number of Participants With Anti-inebilizumab Antibody Formation

    Time frame: Day 1 to Week 52

  14. Subprotocol B and C: Number of Participants With Anti-blinatumomab Antibody Formation

    Time frame: Day 1 to Week 52

  15. Subprotocol C Part A: Percentage of Participants Achieving DAS28-CRP < 2.6

    Time frame: Week 12 and Week 26

  16. Subprotocol C Part A: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) ≤ 2.8

    Time frame: Week 12 and Week 26

  17. Subprotocol C Part A: Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) ≤ 3.3

    Time frame: Week 12 and Week 26

  18. Subprotocol C: Percentage of Participants Achieving American College of Rheumatology (ACR)20 response

    Time frame: Week 12 and Week 26

  19. Subprotocol C: Percentage of Participants Achieving ACR50 Response

    Time frame: Week 12 and Week 26

  20. Subprotocol C: Percentage of Participants Achieving ACR70 Response

    Time frame: Week 12 and Week 26

  21. Subprotocol B Part B and C Part B: Number of Participants Who Experience a TEAE

    Time frame: Day 1 to Week 52

  22. Subprotocol B Part B and C Part B: Number of Participants Who Experience a Serious TEAE

    Time frame: Day 1 to Week 52

  23. Subprotocol B Part A Subgroup 1 and Part B Subgroup 1: Number of Participants With Primary Efficacy Renal Response (PERR)

    Time frame: Week 12, Week 26, Week 38, and Week 52

  24. Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SLE Responder Index 4 (SRI-4)

    Time frame: Week 12, Week 26, Week 38, and Week 52

  25. Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SRI-6

    Time frame: Week 12, Week 26, Week 38, and Week 52

  26. Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by SRI-8

    Time frame: Week 12, Week 26, Week 38, and Week 52

  27. Subprotocol B Part B Subgroup 2: Number of Participants Who are Responders as Defined by BILAG-based Combined Lupus Assessment (BICLA)

    Time frame: Week 12, Week 26, Week 38, and Week 52

  28. Subprotocol C Part B: Percentage of Participants Achieving DAS28-CRP Remission at Week 26

    Time frame: Week 26

  29. Subprotocol C Part B: Percentage of Participants Achieving CDAI Remission at Weeks 12 and 26

    Time frame: Week 12 and Week 26

  30. Subprotocol C Part B: Percentage of Participants Achieving SDAI Remission at Weeks 12 and 26

    Time frame: Week 12 and Week 26

  31. Subprotocol C Part B: Percentage of Participants Who Achieve DAS28-CRP Remission at Week 12 and Sustain Remission at Weeks 26, 38, and 52

    Time frame: Week 12, Week 26, Week 38, and Week 52

07

Study locations

48 of 58 sites recruiting
08

References and documents

Publications

  • Karam S, Boudhabhay I, Jhaveri KD. Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? J Am Soc Nephrol. 2026 Apr 14. doi: 10.1681/ASN.0000001120. Online ahead of print. No abstract available. PubMed 41979896 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Jul 16, 2025
Primary completionEst.
Aug 6, 2028
CompletionEst.
Aug 6, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
IRCCS Ospedale San Raffaele is now Terminated
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    IRCCS Ospedale San Raffaele is now Terminated
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06570798
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jul 16, 2025
Primary completion
Aug 6, 2028 (estimated)
Completion
Aug 6, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inebilizumab · Blinatumomab

Start the discussion